Capacidad de respuesta inmunitaria al Covid-19 en pacientes en hemodiálisis
- Nerea Begoña 1
- Melisa Guzmán 1
- Daniel Germán Gaitán 1
- Concepción Álamo 1
- Jose Ramón Rodriguez 1
- Katia Matilde Pérez 1
- Marta Sánchez 1
- Maria Ángeles Basterrechea 1
- Gabriel de Arriba 1
- 1 Servicio de Nefrología, Hospital Universitario Guadalajara
ISSN: 2530-2787
Year of publication: 2021
Volume: 6
Issue: 1
Pages: 80-87
Type: Article
More publications in: RIECS: Revista de Investigación y Educación en Ciencias de la Salud
Abstract
Patients with end-stage renal disease on hemodialysis have an altered humoral immune response, and a suboptimal seroconversion response to common vaccines. It is not well documented whether patients on maintenance hemodialysis develop antibodies (Ab) in response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We analyzed the immune response against COVID-19 disease in a hospital hemodialysis unit. We conducted an observational retrospective cohort study of 69 hemodialysis patients from the Hospital Universitario de Guadalajara. Wondfo Biotech IgM/IgG antibody rapid test was performed in the third month on 62 patients; Abbott IgG antibody test was performed in the eleventh month on 55 patients. 19 patients were diagnosed with COVID-19: 13 by PCR and 6 by antibody testing. 11 patients suffered from severe COVID-19 illness and required admission to hospital. In the third month 12 patients had detectable Ab, 6 of which had been asymptomatic. In the eleventh month 9 patientshad IgG at an optimal Ab titer, two thirds of them had suffered severe disease. All the patients who suffered severe COVID-19 maintained IgG at eleventh month. All patients diagnosed with COVID-19 who tested negative for IgG antibody in the eleventh monthwhere asymptomatic. In our population, the presence and maintenance of an immune response against SARS Cov2 was associated with a history of severe COVID-19 illness. Indeterminate serological results were associated with oligosymptomatic cases.